Dissemond Joachim, Grabbe Stephan
Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen.
MMW Fortschr Med. 2006 Sep 21;148(38):42-4.
Currently, psoriasis is seen as a T-cell-mediated autoimmune disease that is characterized by an increased expression of pro-inflammatory cytokines. The clarification of this pathogenetic cascade uncovered a number of points of departure for the development of causal therapy and led to the introduction of new medications--the so-called biologics. The following have already been approved in Germany: infliximab, etanercept, efalizumab and adalimumab. These are described, and their advantages and disadvantages in the clinical setting are discussed.
目前，银屑病被视为一种由T细胞介导的自身免疫性疾病，其特征在于促炎细胞因子的表达增加。对这一发病机制级联反应的阐明揭示了因果治疗发展的多个切入点，并导致了新药物——即所谓的生物制剂的引入。以下药物已在德国获批：英夫利昔单抗、依那西普、依法利珠单抗和阿达木单抗。本文将对这些药物进行描述，并讨论它们在临床应用中的优缺点。
